L
Liza A. Vergara
Researcher at University of Queensland
Publications - 21
Citations - 1571
Liza A. Vergara is an academic researcher from University of Queensland. The author has contributed to research in topics: Randomized controlled trial & Pentoxifylline. The author has an hindex of 8, co-authored 17 publications receiving 1446 citations.
Papers
More filters
Journal ArticleDOI
Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial
Sunil V. Badve,Sunil V. Badve,Lei Zhang,Lei Zhang,Jeff S. Coombes,Elaine M. Pascoe,Alan Cass,Philip Clarke,Paolo Ferrari,Stephen P. McDonald,Alicia T. Morrish,Eugenie Pedagogos,Vlado Perkovic,Vlado Perkovic,Donna Reidlinger,Anish Scaria,Rowan G. Walker,Liza A. Vergara,Carmel M. Hawley,Carmel M. Hawley,David W. Johnson,David W. Johnson +21 more
TL;DR: Serum alkaline phosphatase was associated with severity of ESA resistance in ESA-resistant patients with CKD, and large prospective studies are required to confirm this association.
Journal ArticleDOI
The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial
Lei Zhang,Jeff S. Coombes,Elaine M. Pascoe,Sunil V. Badve,Kim Dalziel,Alan Cass,Philip Clarke,Paolo Ferrari,Stephen P. McDonald,Alicia T. Morrish,Eugenie Pedagogos,Vlado Perkovic,Donna Reidlinger,Anish Scaria,Rowan G. Walker,Liza A. Vergara,Carmel M. Hawley,David W. Johnson +17 more
TL;DR: Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.
Journal ArticleDOI
Conducting clinical trials during the COVID-19 pandemic-a collaborative trial network response.
Laura Robison,Yeoungjee Cho,Yeoungjee Cho,Andrea K. Viecelli,Andrea K. Viecelli,David W. Johnson,David W. Johnson,David W. Johnson,Carmel M. Hawley,Carmel M. Hawley,Carmel M. Hawley,Andrea Valks,Peta-Anne Paul-Brent,Ruth Stastny,Julie M. Varghese,Charani Kiriwandeniya,Elaine M. Pascoe,Liza A. Vergara,Magid Fahim,Magid Fahim,Neil Boudville,Neil Boudville,Rathika Krishnasamy,Rathika Krishnasamy,Donna Reidlinger +24 more
TL;DR: The Australasian Kidney Trials Network (AKTN) as mentioned in this paper is an established collaborative research group known for conducting investigator-initiated global clinical trials, had to efficiently respond and adapt to the changing landscape during COVID-19.
Journal ArticleDOI
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial
Matthew A Roberts,Darsy Darssan,Sunil V. Badve,Robert P. Carroll,Magid Fahim,Brian Haluska,Carmel M. Hawley,Nicole M. Isbel,Mark R. Marshall,Elaine M. Pascoe,Eugenie Pedagogos,Helen Pilmore,Paul Snelling,Tony Stanton,Ken-Soon Tan,Andrew Tonkin,Liza A. Vergara,Francesco L. Ierino +17 more
TL;DR: NT-proBNP and hs-TnT were associated with GLS, however, changes in levels of the biomarkers from baseline to 12 months were not different between groups randomized to carvedilol and placebo.
Journal ArticleDOI
The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study
Matthew A Roberts,Helen Pilmore,Francesco L. Ierino,Sunil V. Badve,Sunil V. Badve,Alan Cass,Amit X. Garg,Carmel M. Hawley,Carmel M. Hawley,Nicole M. Isbel,Henry Krum,Elaine M. Pascoe,Andrew Tonkin,Liza A. Vergara,Vlado Perkovic +14 more
TL;DR: The Beta‐blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study aims to determine the feasibility of a large‐scale randomized controlled trial with clinical endpoints comparing the beta‐blocking agent carvedilol with placebo in patients receiving dialysis.